EGFR and non-small cell lung carcinoma: The advent of targeted therapies has substantially improved the prognosis of patients harboring epidermal growth factor receptor (EGFR) mutations, with EGFR tyrosine kinase inhibitors (TKIs) providing markedly longer progression-free survival compared with chemotherapy (18.9 months vs. 6.3 months) in NSCLC patients (3, 4).